Oxurion NV (OXUR) - Total Assets
Based on the latest financial reports, Oxurion NV (OXUR) holds total assets worth €4.98 Million EUR (≈ $5.82 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Oxurion NV - Total Assets Trend (2006–2024)
This chart illustrates how Oxurion NV's total assets have evolved over time, based on quarterly financial data. Also see Oxurion NV (OXUR) market capitalisation for the company's overall valuation and market capitalisation.
Oxurion NV - Asset Composition Analysis
Current Asset Composition (December 2024)
Oxurion NV's total assets of €4.98 Million consist of 63.0% current assets and 37.1% non-current assets. Review total liabilities of Oxurion NV to assess the company's total debt and financial obligations.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 8.0% |
| Accounts Receivable | €2.36 Million | 41.5% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €0.00 | 0.0% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2006–2024)
This chart illustrates how Oxurion NV's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See OXUR stock price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Oxurion NV's current assets represent 63.0% of total assets in 2024, a decrease from 91.7% in 2006.
- Cash Position: Cash and equivalents constituted 8.0% of total assets in 2024, down from 85.8% in 2006.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 6.0% in 2006.
- Asset Diversification: The largest asset category is accounts receivable at 41.5% of total assets.
Oxurion NV Competitors by Total Assets
Key competitors of Oxurion NV based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.98 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
USA | $792.26 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
Oxurion NV - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.17 | 0.08 | 5.53 |
| Quick Ratio | 0.17 | 0.08 | 5.52 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €-13.96 Million | €-17.77 Million | €33.18 Million |
Oxurion NV - Advanced Valuation Insights
This section examines the relationship between Oxurion NV's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.25 |
| Latest Market Cap to Assets Ratio | 0.04 |
| Asset Growth Rate (YoY) | -13.1% |
| Total Assets | €5.70 Million |
| Market Capitalization | $248.85K USD |
Valuation Analysis
Below Book Valuation: The market values Oxurion NV's assets below their book value (0.04x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Oxurion NV's assets decreased by 13.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Oxurion NV (2006–2024)
The table below shows the annual total assets of Oxurion NV from 2006 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €5.70 Million ≈ $6.66 Million |
-13.05% |
| 2023-12-31 | €6.55 Million ≈ $7.66 Million |
-45.38% |
| 2022-12-31 | €11.99 Million ≈ $14.02 Million |
-36.46% |
| 2021-12-31 | €18.88 Million ≈ $22.07 Million |
-44.94% |
| 2020-12-31 | €34.28 Million ≈ $40.08 Million |
-47.28% |
| 2019-12-31 | €65.03 Million ≈ $76.03 Million |
-43.39% |
| 2018-12-31 | €114.86 Million ≈ $134.29 Million |
-23.65% |
| 2017-12-31 | €150.44 Million ≈ $175.88 Million |
+23.68% |
| 2016-12-31 | €121.64 Million ≈ $142.21 Million |
-32.03% |
| 2015-12-31 | €178.95 Million ≈ $209.21 Million |
-18.92% |
| 2014-12-31 | €220.71 Million ≈ $258.04 Million |
-18.60% |
| 2013-12-31 | €271.15 Million ≈ $317.01 Million |
+13.37% |
| 2012-12-31 | €239.17 Million ≈ $279.62 Million |
+85.28% |
| 2011-12-31 | €129.09 Million ≈ $150.92 Million |
-9.69% |
| 2010-12-31 | €142.94 Million ≈ $167.11 Million |
+41.22% |
| 2009-12-31 | €101.22 Million ≈ $118.34 Million |
+50.62% |
| 2008-12-31 | €67.20 Million ≈ $78.57 Million |
+29.24% |
| 2007-12-31 | €52.00 Million ≈ $60.79 Million |
+39.28% |
| 2006-12-31 | €37.33 Million ≈ $43.65 Million |
-- |
About Oxurion NV
Oxurion NV, a biopharmaceutical company, develops medicines to prevent blindness in Belgium. The company is developing ophthalmic treatments to preserve vision for patients with retinal disorders, including geographic atrophy and age-related macular degeneration. The company was formerly known as ThromboGenics NV and changed its name to Oxurion NV in September 2018. Oxurion NV was founded in 1991… Read more